TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 0-2 months (must be gestational age 37 to 41 weeks)~* Scheduled to undergo routine contrast-enhanced liver MRI~* Able to comly with the study procedures~Exclusion Criteria:~* Scheduled for any intervention (except lumbar puncture and bone marrow aspiration) during the study period~* If receiving chemotherapy, may have a change in treatment during the study period~* Contraindication for MRI~* Renal insufficiency (estimated glomerular filtration rate \< 80% of age-adjusted normal mean value using the Schwartz formula)~* Acute renal failure~* Clinically relevant abnormal laboratory parameter, ie, greater than 3 times the upper limit of the normal range, in particular, liver enzymes and renal function. (Note: if elevations in liver enzyme levels are consistent with the underlying hepatobiliary disease, then the subject may be enrolled.)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 2 Months
- Healthy Volunteers: f

Study Arms:
- Gadoxetate disodium (Eovist/Primovist, BAY86-4873) (Type: EXPERIMENTAL): Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole \[mmol\]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent \[%\] solution) manually.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Yttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed CD19-positive (\> 25% by flow cytometry evaluation of bone marrow blasts) disease of 1 of the following types:~  * Primary refractory or relapsed acute lymphoblastic leukemia (ALL) defined as persistent disease following a minimum of two different standard effective chemotherapy induction attempts at time of diagnosis or at relapse~ * Chronic Lymphocytic leukemia (CLL) following blast crisis (≥15% bone marrow blasts following a minimum of one standard effective chemotherapy induction attempt)~* Human anti-mouse antibody (HAMA) must be negative~* Patients who have relapsed ≥ 60 days following an autologous or allogeneic transplant are eligible if all other eligibility criteria are met~* No active central nervous system (CNS) disease~* ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%~* Life expectancy \> 8 weeks~* Total bilirubin ≤ 2.5 times upper limit of normal (ULN)~* AST and ALT ≤ 2.5 times ULN~* Creatinine normal OR creatinine clearance ≥ 60 mL/min~* LVEF ≥ 45% by MUGA/ECHO~* Oxygen saturation on room air \> 92% and no oxygen requirement~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients mus use effective contraception~Exclusion criteria:~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to of yttrium Y 90 anti-CD19 antibody BU-12 or other agents used in study~* Uncontrolled illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness/social situations that would limit compliance with study requirements~* HIV-positive~* Active graft-vs-host disease~* Less than 4 weeks since prior agents and recovered~* Less than 7 days since prior therapy with any biologic agent, defined as a growth factor or cytokine~* Less than 3 months since prior antibody or biologic anticancer therapy (e.g., alemtuzumab or epratuzumab)~* Other concurrent investigational agents~* Patients with peripheral blasts \> 5,000/uL may receive concurrent hydroxyurea

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 111 In-BU-12 (Type: EXPERIMENTAL): 111In-BU-12 is the 111Indium-labeled murine monoclonal antibody used for imaging and dosimetry.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have recently diagnosed (\< than 6 months prior to screening visit date), pathologically confirmed, non-metastatic SCC of the oral cavity, oropharynx, hypopharynx or larynx that will be treated with CRT as first-line treatment; subjects with a history of surgical management (approximately 4-6 weeks before RT with sufficient time for post-surgical healing) are eligible~* Have a plan to receive a continuous course of conventional external beam irradiation delivered by intensity-modulated radiotherapy (IMRT) as single daily fractions of 2.0 to 2.2 Gy, with a cumulative radiation dose between 55 and 72 Gy.~* Have a plan to receive a standard cisplatin CT regimen administered tri-weekly (80 to 100 mg/m2, on Days 0, 21, and 42) or weekly (30 to 40 mg/m2) or a standard carboplatin regimen administered weekly (100 mg/m2)~* Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1~* CRP \< 80 mg/L~* Have adequate hematopoietic, hepatic, and renal function at the screening visit~Exclusion Criteria:~* Tumor of the lips, sinuses, salivary glands, nasopharynx or unknown primary tumor~* Metastatic disease (M1) Stage IV C~* Any prior history of head and neck cancer~* Prior radiation to the head and neck~* Have had a major surgical procedure, other than for HNC, or significant traumatic injury within 4 weeks prior to the initiation of RT; or anticipation of need for a major surgical procedure during the clinical trial~* Active infectious disease, excluding oral candidiasis~* Have OM at the screening visit~* Have a history of hypersensitivity to monoclonal antibody

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Label ALD518 (Type: EXPERIMENTAL): None
- ALD518 Dose 1 (Type: EXPERIMENTAL): None
- ALD518 Dose 2 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Family Planning Counseling for Women With Chronic Medical Conditions in an Inpatient Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Currently admitted to the hospital~* Has one or more qualifying chronic medication conditions listed in their chart (hypertension, obesity with BMI\>35, diabetes, current or history of breast cancer, rheumatoid arthritis, sickle cell disease, or lupus)~Exclusion Criteria:~* Currently pregnant~* Using surgical or non-surgical contraception~* Immediately post-partum or admitted to the gynecology service~* Non-English speaking~* Non-verbal or too ill to consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Bedside Family Planning Counseling (Type: EXPERIMENTAL): Patient is screened for pregnancy intention and then has a bedside family planning counseling session with the investigator taking into account pregnancy intention, medical conditions, medications, and previous contraception used. At the end of the conversation, if patient is desiring contraception, the patient is offered three contraception options (as appropriate for their medical conditions and paid for as part of the study) to be initiated prior to discharge: Etonogestrel implant, medroxyprogesterone 150 mg IM injection, or a year's supply of oral contraception pills.
- Flyer (Type: EXPERIMENTAL): Patient is given a flyer that recommends they discuss pregnancy intention and contraception with their OB/GYN or primary care physician.
- Routine care (Type: NO_INTERVENTION): Patients receive a deception consent so as not to influence them by the consent process. Consent states that the purpose of the project is to study patterns of birth control usage of women admitted to the hospital. Patient is not given any further intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing the Management of Postpartum Urinary Retention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age greater than or equal to 18.~2. Vaginal or cesarean delivery at term (37 weeks gestational age or later) of live-born infants.~3. English or Spanish speaking and reading.~Exclusion Criteria:~1. Adults unable to consent.~2. Women under the age of 18.~3. Women who are currently pregnant (All women in the study will have already delivered).~4. Prisoners or detained individuals.~5. Women who chronically use a urinary catheter for another medical condition.~6. Women with a neurological disease with bladder manifestations (examples: Cerebrovascular accidents, Multiple sclerosis, Parkinson disease, cerebral palsy).~7. Women with preeclampsia requiring magnesium treatment for seizure prevention.~8. Women with prior PUR~9. Women on anticholinergic medications.~10. Women who are actively being treated for a UTI.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GROUP 1 (NonSevere PUR and women without PUR) (Type: NO_INTERVENTION): Women in GROUP 1 will be prospectively observed to characterize their clinical outcomes.
- GROUP 2 (Severe PUR) (Type: EXPERIMENTAL): Women in GROUP 2 will be a randomized to either 3 or 7 days of indwelling catheterization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Measurement of Arch Motion After Bunion Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older.~* Women.~* Able to comprehend the risks associated with the study.~* Able to complete the paperwork required for enrollment.~* Able to walk without assistance of another individual.~Exclusion Criteria:~* Pregnancy~* History of great toe, forefoot or arch surgery, or severe traumatic injury.~* Reduced ankle or great toe motion that impairs the ability to walk.~* Observed evidence of foot deformity other than bunion.~* Insensate to skin sensation testing which could indicate neuropathy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Bunion (Type: None): Patients being treated for foot bunion with surgery.
- Controls (normal foot) (Type: None): Participants in this group will not undergo surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients who are scheduled to receive ATG 2.5mg/kg/day for 3 days as part of the preparative regimen for HSCT, as determined by the responsible HSCT physician.~* Written, informed consent~Exclusion Criteria:~* Hypersensitivity to rabbit proteins or to any product excipients~* Active acute or chronic infections, which would contraindicate any additional immunosuppression~* Known pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Thymoglobulin (Type: EXPERIMENTAL): Thymoglobulin 7.5 mg/kg/course prior to HSCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Ischemic cardiomyopathy~* Ejection Fraction (EF) \<= 35%~* QRS duration \>= 120 msec~* Standard heart failure (HF) oral medications for at least 1 month~* Evidence of mechanical dyssynchrony~* NYHA Class III or IV~Exclusion Criteria:~* Persistent or chronic atrial fibrillation (AF)~* Hemodynamically unstable or uncontrolled arrhythmias~* Unstable angina~* Aortic valve (AV) insufficiency or stenosis~* Mitral valve (MV) regurgitation \> 2+~* Active infection~* Contraindications for heparin~* Dependence on atrial pacing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All consecutive adult patients (age \> 40) undergoing standard (non-minimally invasive) coronary artery bypass surgery and/or aortic valve surgery will be approached for enrollment.~* All patients must be able to provide informed consent and comply with the 3 month follow-up.~* For women of reproductive capability, contraception is necessary and required.~Exclusion Criteria:~* Epidermal growth factor receptor (eGFR) \< 30 mL/min/1.73 m\^2, serum creatinine \> 2.5 mg/dL or requiring dialysis~* Known permanent or current atrial fibrillation (history of paroxysmal atrial fibrillation allowed if in sinus rhythm at present)~* Allergy to colchicine or already treated with colchicine.~* Known blood dyscrasia (acute or chronic leukemia, pancytopenia, aplastic anemia, leukopenia)~* Known serious gastrointestinal disease~* Known severe liver disease (cirrhosis, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2x the upper limit of normal, Model End Stage Liver Disease (MELD) score \> 20)~* Women of childbearing potential not using contraception.~* Patients with HIV or AIDS as the use of protease inhibitors can result in serious colchicine toxicity.~* Patients who are treated with strong CYP3A4 inhibitors (clarithromycin/erythromycin, chloramphenicol, ketoconazole/itraconazole, and nefazodone).~* There is a risk of rhabdomyolysis with the use of digoxin and colchicine, we will exclude patients who require ongoing treatment with digoxin.~* Inability or unwillingness of the individual to give written informed consent.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): A placebo pill (identical to the study drug Colchicine) will be given in a double-blinded fashion to study participants randomized to placebo.
- Colchicine (Type: EXPERIMENTAL): Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* Inclusion Criteria:~  * Patients with T1a or T2a squamous cell carcinoma of the glottic larynx (tumor limited to one vocal cord with normal cord mobility).~ * Patients must be able to read and write English to comply with the questionnaire portions of the protocol.~ * ECOG performance status of 0 or 1.~* Exclusion Criteria:~  * Patients with verrucous or adenocarcinoma~ * Patients with T1 tumors on both cords (T1b)~ * Patients with T2b-T4 true larynx tumors~ * Patients with primary supraglottic tumors that involve the true larynx~ * Patients with a prior or concurrent malignancy (other than nonmelanoma skin cancer or carcinoma in-situ of the cervix) are ineligible unless the previous cancer was treated 5 years or more prior to the current tumor and the patient has remained continually disease free~ * Patients who have received prior radiation to the head and neck~ * Pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMRT Radiation (Type: EXPERIMENTAL): All subjects will be treated using IMRT with the standard fractionation for T1a glottic cancer at Fox Chase Cancer Center: 63 Gy in 28 fractions; 6 for T1a and 65.25 Gy in 29 fractions; 33 for T2a. Treatment will be followed by functional assessments performed at months 1,3,6,12,and 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of 4975 in Patients Undergoing Total Hip Replacement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female aged 18 to 85 years with an American Society of Anesthesiologists (ASA) status of I, II, III~* Planning to undergo unilateral THA~* In good health and capable of undergoing THA with spinal block and sedation anesthesia~* No additional planned surgeries during the course of the trial~* Willing and able to complete the study procedures and pain scales and to communicate meaningfully in English~Key Exclusion Criteria:~* A body mass index greater than 40~* Known bleeding disorder or is taking agents affecting coagulation preoperatively~* A medical condition that could adversely impact the patient's participation, safety, or conduct of the study~* Diabetes mellitus with a known HbA1C\>9.5 or a history of prolonged uncontrolled diabetes~* Previous hip arthroplasty of the same hip~* Participated in another clinical trial within 30 days of the planned hip surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Study treatment, 4975, is instilled directly into surgical site
- 2 (Type: PLACEBO_COMPARATOR): Placebo is instilled directly into surgical site

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Colometer - A Real Time Quality Improvement Feedback System for Screening Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients: patients categorized as normal risk who have been referred for screening colonoscopy at the Forzani \& MacPhail Colon Cancer Screening Centre in Calgary, Alberta~* Endoscopists: Gastroenterologists with practices at the Forzani \& MacPhail Colon Cancer Screening Centre, Calgary, Alberta~Exclusion Criteria:~* Patients: patients who are not categorized as normal risk

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Colometer (Type: EXPERIMENTAL): Colometer software will be engaged during the colonoscopy to provide real time feedback to the endoscopist.
- Sham Software (Type: SHAM_COMPARATOR): An identical set-up to the experimental arm but with a green band showing across the top for the duration of the colonoscopy.
- Control (Type: NO_INTERVENTION): Recordings of colonoscopies made without Colometer or sham feedback during the course of the colonoscopy will be evaluated retrospectively using the Colometer software.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Refractory Status Epilepticus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with refractory status epilepticus not due to cerebral anoxia, needing coma induction for clinical management.~Exclusion Criteria:~* Age \< 16 years old.~* Known pregnancy.~* Cerebral anoxia as SE etiology.~* Epilepsia partialis continua (simple partial SE).~* Known intolerance to the study drugs.~* Known mitochondrial disorder, hyperlipidemia, or significant rhabdomyolysis.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): propofol, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined
- 2 (Type: ACTIVE_COMPARATOR): thiopental/pentobarbital, 2mg/kg as bolus, then titrated up to EEG burst-suppression as a continuous infusion; no maximum doses defined

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues